Peter James O'dwyer

Peter James O'dwyer's AcademicInfluence.com Rankings

Peter James O'dwyer

Biology

#9396

World Rank

#12597

Historical Rank

Molecular Biology

#1282

World Rank

#1309

Historical Rank

Neuroscience

#1369

World Rank

#1416

Historical Rank

biology Degrees

Download Badge

Biology

Peter James O'dwyer's Degrees

PhD Biomedical Sciences University of California, San Francisco
Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Peter James O'dwyer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter James O'dwyer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Inhibition of mutated, activated BRAF in metastatic melanoma. (2010) (3502)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. (2007) (2262)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans (2011) (1173)
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (1992) (900)
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. (2006) (843)
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy (2014) (776)
Phase II trial of sorafenib in advanced thyroid cancer. (2008) (670)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (2006) (645)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (2015) (518)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. (2012) (486)
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme (2014) (414)
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. (2002) (403)
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. (2009) (399)
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. (2010) (390)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. (2007) (384)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma (2013) (372)
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. (2018) (368)
Etoposide (VP-16-213). Current status of an active anticancer drug. (1985) (366)
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients (2015) (354)
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (2005) (347)
Gene expression patterns in ovarian carcinomas. (2003) (333)
Mechanisms of hypertension associated with BAY 43-9006. (2006) (317)
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma (2014) (311)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer (2011) (310)
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. (2003) (307)
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. (1995) (307)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment (2014) (302)
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. (2010) (297)
Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. (1994) (255)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) (2011) (246)
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. (1985) (240)
Phase I clinical trial design in cancer drug development. (2000) (221)
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. (1996) (209)
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293 (1996) (202)
Combined MTOR and autophagy inhibition (2014) (199)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies (2017) (197)
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. (2010) (191)
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. (1995) (191)
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma (2008) (186)
Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy (2007) (180)
Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy (2013) (179)
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. (2019) (172)
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). (2015) (169)
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. (1996) (156)
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. (2006) (156)
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells (2005) (152)
Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. (1991) (146)
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. (2009) (145)
A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel (2008) (145)
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. (1993) (135)
Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). (2006) (133)
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). (1999) (128)
Clinical Pharmacokinetics and Administration of Established Platinum Drugs (2012) (127)
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. (2006) (125)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. (2006) (124)
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases (2009) (115)
Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. (2004) (111)
Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. (2006) (109)
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) (2020) (108)
Changes in the concentrations of plasma selenium and selenoproteins after minor elective surgery: further evidence for a negative acute phase response? (1998) (106)
Clinical studies of reversal of drug resistance based on glutathione. (1998) (105)
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. (2007) (105)
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (2020) (103)
Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin (2005) (101)
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. (1992) (101)
2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. (1988) (99)
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. (1990) (99)
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. (2004) (97)
Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia. (1995) (97)
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development. (2016) (96)
A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. (2006) (96)
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation (2019) (93)
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors (2019) (93)
A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. (1991) (92)
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. (2003) (91)
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. (2004) (91)
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. (1994) (90)
Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. (1996) (88)
Role of thymidine in biochemical modulation: a review. (1987) (86)
Involvement of NF-κB in the induction of NAD(P)H: Quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C (1995) (85)
Epidermal growth factor receptor-targeted therapy in colorectal cancer. (2002) (84)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma (2019) (83)
Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. (2018) (83)
Clinical Status of Cisplatin, Carboplatin, and Other Platinum‐Based Antitumor Drugs (2006) (81)
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors (2011) (81)
Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. (1988) (80)
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). (1999) (80)
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. (2013) (78)
High rate of consent to bank biologic samples for future research: the Eastern Cooperative Oncology Group experience. (2002) (78)
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). (2015) (78)
Role of Jun and Jun kinase in resistance of cancer cells to therapy. (2003) (76)
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. (2001) (76)
Glutathione and drug resistance. (1996) (76)
Race, treatment preferences, and hospice enrollment: Eligibility criteria may exclude patients with the greatest needs for care (2009) (75)
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial (2018) (75)
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. (2019) (75)
Monoclonal antibodies in the treatment of colorectal cancer. (2004) (74)
Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial (2013) (70)
Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer. (2019) (68)
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. (2020) (68)
Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab (2012) (67)
The terrible choice: re-evaluating hospice eligibility criteria for cancer. (2009) (64)
Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. (2003) (62)
Teniposide: a review of 12 years of experience. (1984) (62)
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo (2005) (62)
Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. (2001) (61)
Antisense therapeutics: lessons from early clinical trials (2001) (60)
Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. (1986) (59)
Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. (1994) (57)
A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA). (2014) (57)
Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. (2008) (56)
Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma (2019) (55)
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. (2019) (55)
Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder (1997) (55)
Phase I/pharmacokinetic reevaluation of thioTEPA. (1991) (54)
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer (2005) (54)
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. (2020) (54)
Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. (1994) (53)
Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma (2005) (52)
Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. (2006) (51)
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. (2007) (50)
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer (2020) (48)
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. (2002) (48)
Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. (1996) (47)
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial (2011) (46)
Biochemical modulation: application of laboratory models to the clinic. (1986) (45)
Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. (2003) (45)
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. (2001) (45)
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. (2005) (45)
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. (2002) (45)
Hypersensitivity reactions to teniposide (VM-26): an analysis. (1986) (45)
The role of glutathione in drug resistance. (1990) (43)
Macrophage Migration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell Lines (2005) (42)
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study (2011) (42)
Acivicin: a new glutamine antagonist in clinical trials. (1984) (42)
Dielectrophoretic Capture and Genetic Analysis of Single Neuroblastoma Tumor Cells (2014) (41)
Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. (2002) (40)
Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines. (2007) (40)
Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. (1997) (40)
Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. (2007) (40)
Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. (1999) (39)
Association of severe and fatal infections and treatment with pentostatin. (1986) (39)
Evaluation of the long term outcome of patients with extremity desmoids. (2004) (39)
Hypersensitivity reactions induced by etoposide. (1984) (38)
Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. (2006) (38)
Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. (1993) (38)
Overview of phase II trials of MTA in solid tumors. (1999) (38)
Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy. (1996) (37)
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. (2013) (36)
Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. (2004) (36)
Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. (1994) (35)
Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. (2009) (35)
Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. (2011) (34)
Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. (1995) (34)
Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. (2019) (33)
Axillary dissection in primary breast cancer. (1991) (33)
Homoharringtonine--perspectives on an active new natural product. (1986) (33)
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. (1992) (33)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors (2009) (33)
Phase I pharmacokinetic study of intraperitoneal etoposide. (1991) (32)
The present and future of angiogenesis-directed treatments of colorectal cancer. (2006) (32)
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. (1995) (31)
Gene expression profiling of human ovarian tumours (2006) (31)
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. (2020) (31)
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors (2018) (31)
A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer. (1998) (31)
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. (2007) (30)
Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. (2018) (30)
Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells. (1997) (30)
Phase II trial of sorafenib in patients with advanced thyroid cancer. (2011) (30)
Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma (2005) (30)
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer (2019) (29)
How should we design supportive cancer care? The patient's perspective. (2008) (29)
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors (2005) (29)
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer (2001) (29)
Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation inBRCA1, BRCA2orPALB2 (2019) (28)
NF-κB Activation by the Chemopreventive Dithiolethione Oltipraz Is Exerted through Stimulation of MEKK3 Signaling* (2004) (28)
Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT). (2011) (28)
Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. (1997) (28)
JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to Chemotherapy (2016) (28)
Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603). (2010) (27)
Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule (1999) (27)
Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC). (2019) (26)
Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts. (2017) (26)
Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer. (2018) (26)
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131) (2020) (26)
The chemopreventive agent oltipraz stimulates repair of damaged DNA. (1997) (26)
Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. (1995) (26)
Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial (2004) (26)
Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. (1997) (25)
Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial. (2018) (25)
Clinical reversal of drug resistance in ovarian cancer. (1993) (25)
A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991 (2007) (25)
Current status of oxaliplatin in colorectal cancer. (2003) (24)
A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate. (2002) (24)
Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers (2016) (24)
Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. (2012) (24)
A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203) (2008) (24)
A phase II study of high-dose bevacizumab in combination with irinotecan , 5-fluorouracil , leucovorin , as initial therapy for advanced colorectal cancer : results from the eastern cooperative oncology group study E 2200 (2006) (24)
Involvement of NF-kappa B in the induction of NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C. (1995) (23)
Value of biopsy in the assessment of a retroperitoneal mass. (2006) (23)
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. (1998) (23)
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. (2013) (23)
A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors (2019) (22)
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. (1999) (22)
LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) (2015) (22)
Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment. (1996) (21)
Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study. (2016) (21)
Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. (2005) (21)
Abstract B080: Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) precision medicine trial (2018) (21)
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer (2020) (21)
Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. (2000) (20)
NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership (2016) (20)
Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors (2007) (20)
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. (2020) (20)
MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach (2018) (20)
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. (1998) (20)
Clinical, pharmacokinetic and biological studies of topotecan (2004) (19)
Treatment of early stage Hodgkin’s disease: A randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone (1985) (19)
Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. (2003) (19)
A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. (2014) (19)
Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach (2004) (18)
Phase I and Pharmacokinetic Study of the Cytotoxic Ether Lipid Ilmofosine Administered by Weekly Two-Hour Infusion in Patients with Advanced Solid Tumors (2004) (18)
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma (2017) (18)
A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer. (2004) (18)
Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. (1995) (18)
Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension. (2004) (17)
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens. (1991) (17)
Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV) (2005) (17)
A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. (1997) (17)
Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. (2003) (17)
PHASE II TRIAL OF PACLITAXEL IN PATIENTS WITH ADVANCED COLON CANCER PREVIOUSLY UNTREATED WITH CYTOTOXIC CHEMOTHERAPY: AN EASTERN COOPERATIVE ONCOLOGY GROUP TRIAL (PA286) (1996) (17)
Strong Signature of Natural Selection within an FHIT Intron Implicated in Prostate Cancer Risk (2008) (17)
Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. (2006) (17)
A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer. (2013) (17)
Phase I trial of N-methylformamide (NMF, NSC 3051). (1985) (16)
Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis (2016) (16)
Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. (1991) (16)
Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. (2002) (16)
Tiazofurin: A new antitumor agent (2004) (16)
TNF Signaling through RIP1 Kinase Enhances SN38-Induced Death in Colon Adenocarcinoma (2017) (15)
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. (2004) (15)
Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer. (2017) (15)
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents (2015) (15)
Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule. (1992) (15)
Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines. (1996) (15)
Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial. (2004) (15)
Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma (2018) (15)
ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5- fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/ III rectal cancer receiving either pre or postoperative radiation (RT)/ FU. (2006) (15)
Interaction of heat and hypoxia in modulating transcription of DT diaphorase in human colon adenocarcinoma cells. (1994) (14)
Platinum analogues in preclinical and clinical development (1993) (14)
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors (2021) (14)
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours (2019) (14)
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer (2013) (14)
Trimetrexate: clinical development of a nonclassical antifolate. (1987) (14)
Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. (1996) (13)
Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer. (2015) (13)
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. (2002) (13)
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine (2004) (13)
2'-Deoxycoformycin: Summary and future directions (1984) (13)
Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia. (1988) (12)
Flavone acetic acid (LM 975, NSC 347512) A novel antitumor agent (2004) (12)
Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group's Study E3200. (2006) (12)
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas (1995) (12)
Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. (1994) (12)
Trimetrexate: a new antifol entering clinical trials (2004) (12)
Abstract CT124: A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer (2018) (12)
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience. (1995) (12)
InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease. (2015) (12)
Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. (2004) (12)
Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias. (2006) (11)
Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. (2019) (11)
The role of low-dose PALA in biochemical modulation. (1990) (11)
Follow-up of stage B and C colorectal cancer in the United States and France. (2001) (11)
Chronic dosing of oltipraz in people at increased risk for colorectal cancer. (2001) (11)
Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. (2003) (11)
Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). (2009) (11)
Phase I trial of 5-fluorouracil by 24-hour infusion weekly (1993) (11)
A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy. (2019) (11)
NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial. (2016) (11)
FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). (2014) (10)
Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer. (2015) (10)
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). (2019) (10)
Determination of the platinum drug cis-amminedichloro(2-methylpyridine)platinum(II) in human urine by liquid chromatography-tandem mass spectrometry. (2003) (10)
Pharmacokinetic study of trimetrexate in combination with cisplatin. (1991) (10)
NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. (2018) (10)
612TiPMODUL-A MULTICENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN THERAPY FOR THE 1ST-LINE MAINTENANCE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A SIGNAL-SEEKING APPROACH. (2014) (9)
First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q (2008) (9)
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma (2004) (9)
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer (2019) (9)
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer (2004) (9)
Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide. (1993) (9)
Disruption of Signaling through SEK1 and MKK7 Yields Differential Responses in Hypoxic Colon Cancer Cells Treated with Oxaliplatin (2008) (9)
Biochemical modulation of 5-fluorouracil by PALA. (1990) (8)
A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy. (2015) (8)
Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy. (2015) (8)
Spiromustine: a new agent entering clinical trials (2004) (8)
Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations (2019) (8)
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203) (2018) (8)
Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days (2004) (8)
Abstract P6-13-08: Palbociclib and paclitaxel on an alternating schedule for advanced breast cancer: Results of a phase Ib trial (2016) (8)
FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. (2019) (7)
A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer (2018) (7)
Early treatment-related neutropenia predicts response to palbociclib (2020) (7)
What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report (2020) (7)
Phase I trial of ilmofosine as a 24 hour infusion weekly (2004) (7)
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer (2004) (7)
FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (2016) (7)
Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation. (2016) (7)
FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. (2013) (7)
Clinical Experience: DACH-Based Platinum Drugs (2000) (6)
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network. (1996) (6)
Comparative effectiveness of proton therapy versus photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. (2019) (6)
Pyrazole: preclinical reassessment (1988) (6)
Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF. (1996) (6)
MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience. (2011) (6)
Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice. (1986) (6)
E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. (2014) (6)
Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containingBRCA1andBRCA2mutations (2019) (6)
Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial (2012) (6)
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas (2011) (6)
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel. (2012) (6)
Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT) (2012) (6)
Anaphylactic reactions to diaziquone. (1984) (5)
Development of folates and folic acid antagonists in cancer chemotherapy. (1987) (5)
51LBA Completion of a Phase II study of sorafenib for advanced thyroid cancer (2009) (5)
Indicine N-oxide: clinical use of a pyrrolizidine alkaloid. (1987) (5)
A randomized clinical trial of chemotherapy with gemcitabine/cisplatin/nabpaclitaxel with or without the AXL inhibitor bemcentinib (BGB324) for patients with advanced pancreatic cancer. (2019) (5)
Molecular dimensions and properties of N-[1-(2-hydroxyethyl)-2-nitro-1H-imidazol-1-yl]acetamide (SR2508). (1993) (5)
Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. (2020) (5)
High-performance liquid chromatographic analysis of N,N',N"-triethylenethiophosphoramide in human plasma. (1989) (5)
Comparing the clinical impact of pancreatic cyst surveillance programs: A trial of the ECOG-ACRIN cancer research group (EA2185). (2020) (5)
Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma. (2015) (5)
Phase II trial of topotecan in advanced pancreatic cancer (1993) (5)
Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma (2008) (5)
Drug resistance in ovarian cancer and potential for its reversal (1995) (5)
Chemotherapy for advanced colorectal cancer (2001) (5)
Abstract CT165: Phase II open label trial of minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer (2019) (4)
Phase I study of phosphonacetyl-l-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer (2004) (4)
Patient treatment on a compassionate basis: documentation of high adverse drug reaction rate. (1992) (4)
BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study. (2020) (4)
Current Activities of the Coalition of Cancer Cooperative Groups. (2018) (4)
Abstract P4-13-04: Upregulation of cell cycle pathway genes without loss of RB1 contributes to acquired resistance to single-agent treatment with palbociclib in breast cancer (2016) (4)
Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells. (1995) (4)
Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142). (2016) (4)
High-performance liquid chromatographic determination of ethacrynic acid in human plasma. (1991) (4)
Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. (2020) (4)
Phase II Trials (2004) (4)
Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? (2017) (4)
Schedule as a determinant of cytotoxic drug activity. (1989) (4)
A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174). (2021) (4)
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies (2004) (4)
Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer. (2021) (4)
Biochemical modulation as an approach to reversal of antimetabolite resistance. (1994) (4)
Pharmacology and clinical investigation of SR-2508 (etanidazole). (1991) (4)
A single arm phase II study of rucaparib maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy. (2018) (4)
Phase II Clinical Trials in Oncology (1997) (4)
Abstract P4-22-14: Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer (2017) (4)
Acute Toxicity of Proton Versus Photon Chemoradiation Therapy for Pancreatic Adenocarcinoma: A Cohort Study (2013) (4)
Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. (2018) (4)
Phase I trial of fluorouracil modulation by n-phosphonacetyl-l-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer (2004) (4)
Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. (2020) (4)
Dichloromethotrexate--a critical reassessment. (1985) (4)
Hypersensitivity reactions to deoxycoformycin (2004) (3)
Predictive Biomarkers and Personalized Medicine Association betweenVEGFSplice IsoformsandProgression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab (2012) (3)
Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology (2018) (3)
A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174). (2020) (3)
Evidence for improved pathologic complete response (PCR) rate after preoperative chemoradiotherapy with 5-FU/oxaliplatin (5FU/OX) for rectal cancer. (2006) (3)
P1.46: Phase I Study of Nivolumab + Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort: Track: Advanced NSCLC. (2016) (3)
Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts (2016) (3)
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy in patients with locally advanced pancreatic cancer. (2012) (3)
E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC). (2014) (3)
Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network. (2019) (3)
Platinum complexes for the treatment of cancer (2001) (3)
Interim results of phase II trial of the cyclin-dependent kinase 4/6 inhibitor PD-0332991 in refractory retinoblastoma protein positive germ cell tumors. (2012) (3)
Aggressive Supportive Care Improves Outcomes in the Combined Modality Treatment of Pancreatic and Duodenal Cancer (2007) (3)
Abstract CT085: Randomized phase II trial of hydroxychloroquine in combination with gemcitabine/nab-paclitaxel to inhibit autophagy in pancreatic cancer: A SU2C-funded trial (2018) (3)
Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors (2019) (3)
Pharmacokinetic (PK)/pharmacodynamic (PD) trial of the new generation platinum compound ZD0473 administered as an iv infusion every 21 days (2001) (3)
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen (2005) (3)
Phase I trial of buthionine sulfoximine (BSO) in combination with melphalan (1993) (3)
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors. (2012) (3)
Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer. (1991) (3)
Abstract P2-16-20: Biomarkers to predict response to the CDK 4/6 inhibitor, palbociclib (PD 0332991) in a single-agent phase II trial in advanced breast cancer (2013) (3)
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer (2021) (3)
Preliminary evaluation of response to combination of RAD001 and cetuximab using [18F]-fluorodeoxyglucose positron emission tomography (18FDG-PET) (2008) (2)
Locally advanced pancreatic cancer: maybe not so local. (2016) (2)
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. (1995) (2)
A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer. (2010) (2)
The next generation of targeted therapy trials in colorectal cancer. (2014) (2)
Role of CCL19 and CCL21 chemokines in the response of ovarian tumors to platinum-based chemotherapy (2004) (2)
Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. (2021) (2)
LBA-10MODUL – A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1st-Line Maintenance Treatment of Metastatic Colorectal Cancer (mCRC): A Highly Adaptable Signal-Seeking Approach (2015) (2)
Voluntary submission of biological specimens from cancer clinical trials: An update of the Eastern Cooperative Oncology Group experience. (2009) (2)
Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel. (2011) (2)
Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1. (2011) (2)
Resection of focally progressive gastrointestinal stromal tumours resistant to imatinib therapy. (2012) (2)
Abstract 4500: Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors (2011) (2)
928 Phase I trial of the topoisomerase I inhibitor GG211 as a 72-hour infusion (1995) (2)
O-0001PHASE 2 DOUBLE-BLIND, PLACEBO–CONTROLLED TRIAL OF DASATINIB ADDED TO GEMCITABINE FOR SUBJECTS WITH LOCALLY-ADVANCED PANCREATIC CANCER (LAPC) (2014) (2)
Molecular Triage Trials in Colorectal Cancer (2016) (2)
High-performance liquid chromatographic determination of the S- and R-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine. (1993) (2)
Phase II study of amonafide in advanced and recurrent sarcoma patients (1992) (2)
Irinotecan and UFT/leucovorin in patients with advanced cancers. (2000) (2)
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (1995) (2)
Chromatographic analysis of methylmercaptopurine riboside in human plasma and urine. (1991) (2)
SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma. (1993) (2)
A Phase II trial of weekly infusional 5-fluorouracil in combination with lowdose leucovorin in patients with advanced colorectal cancer (2004) (2)
Adjuvant chemotherapy after trimodality therapy in locally advanced esophageal cancer. (2014) (2)
The Clinical Development of Lurtotecan (2005) (1)
553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J (2020) (1)
A pilot study of galunisertib (LY2157299 monohydrate) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC). (2018) (1)
Neutropenia and response to single agent palbociclib. (2018) (1)
439P Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC) (2020) (1)
Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. (2010) (1)
Cancers of the large bowel and hepatobiliary tract. (2001) (1)
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy (2003) (1)
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination (2004) (1)
Aminothiadiazole: an antineoplastic thiadiazole. (1986) (1)
Phase II study of amonafide (Nafidamide, NSC 308847) in advanced colorectal cancer (1991) (1)
Methodology for the rational development of methotrexate analogs in the clinic. (1987) (1)
A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report. (2012) (1)
High-performance liquid chromatographic method for the determination of AG-331, a novel anti-cancer agent, in human serum and urine using solid-phase extraction and photodiode-array detection. (1995) (1)
Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study. (2017) (1)
MAX2: a convenient index to estimate the average per patient risk of severe toxicity from a chemotherapy regimen. Testing in ECOG studies (Abstract) (2002) (1)
Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma. (2004) (1)
Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma. (1991) (1)
Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. (2013) (1)
Abstract A053: Prevalence of mismatch repair deficiency (dMMR) in the NCI Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) population (2018) (1)
2178 : Preoperative Chemoradiotherapy With 5-Fluorouracil (5-FU) Or 5-FU/oxaliplatin (5FU/OX) for Rectal Cancer Is a Feasible Treatment Strategy in the Elderly (2006) (1)
Signaling through MKK7 is required for oxaliplatin-induced cell death in hypoxic colon adenocarcinoma cell lines (2007) (1)
A phase I, dose-escalation study of the novel antifolate zd9331 in combination with cisplatin in patients with refractory solid malignancies (2001) (1)
Predictive value of the antiangiogenic VEGF splice variant expression for bevacizumab efficacy in the phase III trial of bevacizumab and FOLFOX4 versus FOLFOX4 in previously treated patients with advanced colorectal cancer (ECOG E3200T2). (2012) (1)
AB040. P-08. FOENIX-CCA2: a phase 2 study of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements (2019) (1)
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U. (2021) (1)
Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies (2019) (1)
Cyclin-dependent kinase 4/6 inhibition for the treatment of mature teratoma germ cell tumor: Long-term follow-up of a phase II study. (2016) (1)
MacrophageMigration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell (2005) (1)
P1-17-06: A Phase II Trial of the CDK 4/6 Inhibitor PD0332991 in Women with Advanced Breast Cancer. (2011) (0)
Imaging with [18f]-fluorodeoxyglucose positron emission tomography (FDG-PET) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as markers of drug effect in a phase I dose-escalation study of combined RAD 001 and cetuximab. (2011) (0)
An Internist's Illustrated Guide to Gastrointestinal Surgery, G.Y. Wu, K. Aziz, G.F. Whalen (Eds.). Humana Press (2003), ISBN: 1588290239 (2004) (0)
Markers in Colorectal Cancer and Clinical Trials Based Upon Them (2015) (0)
P3.02c-056 Interim Results From the Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Non-Small Cell Lung Cancer (NSCLC): Topic: IT (2017) (0)
189 POSTER Acquired resistance to oxaliplatin in colon cancer cell lines is associated with up-regulation of G2/M checkpoint (2006) (0)
Effects of Hypoxiaon DetoxicatingEnzymeActivity and Expressionin HT29 Colon Adenocarcinoma Cells (1994) (0)
Abstract 2872: Induction of autophagy in hypoxic HT29 cells requires functional JNK1 (2011) (0)
Results of a feasibility study of I-124 girentuximab in metastatic clear cell renal cell carcinoma (m ccRCC). (2014) (0)
Phase I trial of the novel platinum analog ZD0473 in combination with gemcitabine in patients with advanced cancer (2001) (0)
P1.03-026 Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC (2017) (0)
Increase in blood pressure with sorafenib exposure: Renal cell carcinoma (RCC) versus other solid tumors. (2013) (0)
Characterization of isolated, uncomplicated neutropenia–related to the CDK4/6 inhibitor palbociclib. (2014) (0)
Commentary (Szarka/O'Dwyer): New Antifolates in Clinical Development (1995) (0)
Interim results from the phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC) (2016) (0)
Abstract 3512: Dielectrophoretic capture and genetic analysis of individual disseminated solid tumor cells. (2013) (0)
586 POSTER Modulation of signaling through SEK1 and MKK7 differentially affects oxaliplatin sensitivity in hypoxic colon cancer cell lines (2008) (0)
Improved Rate of Sphincter Sparing Surgery Following Preoperative Chemoradiotherapy for Rectal Cancer With 5-FU/Oxaliplatin (5FU/OX) Compared to 5-Fluorouracil (5-FU) Alone (2007) (0)
Oltipraz, chemopreventive agent activates NF-kB for human NAD(P)H: quinone oxidoreductase gene regulation (2004) (0)
Abstract 2267: Inhibition of autophagy in hypoxic HT29 cells reverses hypoxia-induced resistance to oxaliplatin (2012) (0)
Comparative effectiveness of proton versus photon chemoradiotherapy for patients with private insurance. (2020) (0)
Radiomic profiles via machine learning to predict response, overall survival, and KRAS status in metastatic colorectal tumors treated with FOLFOX/bevacizumab/hydroxychloroquine. (2019) (0)
91 17-allylamino-17-demethoxygeldanamycin overcomes trail resistance in colon cancer cell lines (2004) (0)
Expression in HT 29 Colon Adenocarcinoma Cells Effects of Hypoxia on Detoxicating Enzyme Activity and Updated (2006) (0)
Abstract CT061: Binimetinib in patients with tumors withNRASmutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A (2020) (0)
Phase I and Pharmacokinetic Trial of the Proapoptotic Sulindac Analog CP-461 in Patients with Advanced Cancer 1 (2002) (0)
2207 (2017) (0)
Abstract 87: Differential effects of JNK1 and JNK2 on cell death in hypoxic colon cancer cell lines (2010) (0)
A liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine) platinum(II) (ZD0473) in human plasma ultrafiltrate (2001) (0)
Cisplatin Resistance in Ovarian Cancer Cell Lines Cross-Resistance to Diverse Drugs Is Associated with Primary Updated Version (2006) (0)
Evaluation of response to sorafenib in metastatic thyroid cancer with FDG PET (2008) (0)
Abstract 2521: Combining chemotherapy with autophagy inhibition: Phase I trial of dose-intense temozolomide and hydroxchloroquine in patients with advanced solid tumors (2011) (0)
Analysis of cis-amminedichloro(2-methylpyridine) platinum(II) (ZD0473) in human urine (2001) (0)
Phase I Cl inica l Tria l Des ign in Cancer Drug Development (2000) (0)
2207: A Phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer (2017) (0)
Abstract 1679A: HLTF gene silencing predicts sensitivity to lysosomal autophagy inhibitors in cancer cells. (2013) (0)
Hypoglycemia: not an important side effect of mitoguazone. (1985) (0)
An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. (2012) (0)
Abstracts reprinted from Journal of Clinical Oncology (2007) (0)
2′-Deoxycoformycin (Pentostatin) for Lymphoid Malignancies (2020) (0)
Robert L. Comis: In Memoriam (2017) (0)
PrE0204: A multi-institutional, single arm, two-stage phase II trial of nab-paclitaxel and gemcitabine for first-line treatment of patients with advanced or metastatic cholangiocarcinoma—A PrECOG LLC study. (2017) (0)
Abstract 488: Inhibition of JNK signaling sensitizes hypoxic colon cancer cells to DNA-damaging agents (2014) (0)
Classification of cancers by gene expression profiles from peripheral blood (2003) (0)
Clinical Effects of MGCD265, an oral Tyrosine Kinase Inhibitor, in Combination with Erlotinib or Docetaxel for Treatment of Advanced Gastroesophageal and Nsclc Tumors (2012) (0)
Modulation of glutathione and associated enzymes as a therapeutic strategy (1991) (0)
474 Potentiation of oxaliplatin in colon cancer by JNK inhibition (2014) (0)
A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176). (2021) (0)
Abstract A72: Phase 1 study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo + nab-P in arm A (2016) (0)
Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131) (2019) (0)
Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia (1994) (0)
Erratum: Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (26835–26845) DOI: 10.1073/pnas.1914915116) (2020) (0)
Abstract 2274: RIP1-mediated sensitivity to SN38 induced by TNF in colon adenocarcinoma cell lines (2014) (0)
The clinical horizon of deoxycoformycin (1987) (0)
Clinical Aspects of FUra Metabolism (1986) (0)

This paper list is powered by the following services:

Peter James O'dwyer's Academic­Influence.com Rankings

Peter James O'dwyer's Degrees

Similar Degrees You Can Earn

Why Is Peter James O'dwyer Influential?

Peter James O'dwyer's Published Works

Published Works

Peter James O'dwyer's AcademicInfluence.com Rankings